Triple-negative breast cancer (TNBC), accounting for ~15–20% of breast cancer cases, is classified as triple-negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2). Here, ERBB2 is linked to triple-negative breast carcinoma.